These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15155991)

  • 21. Epidemiological evaluation of onchocerciasis along Ogun River System, southwest Nigeria.
    Sam-Wobo SO; Adeleke MA; Jayeola OA; Adeyi AO; Oluwole AS; Ikenga M; Lawniye F; Gazama J; Kagni A; Kosoko TO; Agbeyangi O; Bankole S; Toé L; Mafiana CF; Yameogo L
    J Vector Borne Dis; 2012 Jun; 49(2):101-4. PubMed ID: 22898482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteinuria and onchocerciasis in an endemic area in Cameroon under community-based treatment with ivermectin.
    Ebong CE; Alemnji GA; ; Ashuntantang G; Asonganyi T
    Trop Doct; 2007 Jul; 37(3):156-8. PubMed ID: 17716503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of four years of large-scale ivermectin treatment with low therapeutic coverage on the transmission of Onchocerca volvulus in the Mbam valley focus, central Cameroon.
    Pion SD; Clément MC; Boussinesq M
    Trans R Soc Trop Med Hyg; 2004 Sep; 98(9):520-8. PubMed ID: 15251400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Onchocerciasis in Anambra State, Southeast Nigeria: endemicity and clinical manifestations.
    Mbanefo EC; Eneanya CI; Nwaorgu OC; Otiji MO; Oguoma VM; Ogolo BA
    Postgrad Med J; 2010 Oct; 86(1020):578-83. PubMed ID: 20702432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ivermectin dose assessment without weighing scales.
    Alexander ND; Cousens SN; Yahaya H; Abiose A; Jones BR
    Bull World Health Organ; 1993; 71(3-4):361-6. PubMed ID: 8324855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors affecting the attrition of community-directed distributors of ivermectin, in an onchocerciasis-control programme in the Imo and Abia states of south-eastern Nigeria.
    Emukah EC; Enyinnaya U; Olaniran NS; Akpan EA; Hopkins DR; Miri ES; Amazigo U; Okoronkwo C; Stanley A; Rakers L; Richards FO; Katabarwa MN
    Ann Trop Med Parasitol; 2008 Jan; 102(1):45-51. PubMed ID: 18186977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Mass treatment of onchocerciasis in 1996].
    Chovet M; Carlier C; Queguiner P; Mariko S
    Med Trop (Mars); 1995; 55(4 Pt 2):425-8. PubMed ID: 10906977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Ivermectin in the treatment of onchocerciasis: feasibility, compliance and efficacy of a mass treatment].
    Awissi D; Heuschkel C; Banla M; Schulz-Key H
    Bull Soc Pathol Exot; 1991; 84(5 Pt 5):739-49. PubMed ID: 1819423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of persons who complied with and failed to comply with annual ivermectin treatment.
    Brieger WR; Okeibunor JC; Abiose AO; Ndyomugyenyi R; Wanji S; Elhassan E; Amazigo UV
    Trop Med Int Health; 2012 Jul; 17(7):920-30. PubMed ID: 22575028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence of onchocerciasis in villages in Enugu and Ogun states in Nigeria following many rounds of mass distribution of ivermectin.
    Ekpo UF; Eneanya OA; Nwankwo EN; Soneye IY; Weil GJ; Fischer PU; Nwaorgu OC
    BMC Infect Dis; 2022 Nov; 22(1):832. PubMed ID: 36357828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of community compliance with annual ivermectin treatment of onchocerciasis in Patigi, Nigeria.
    Oyibo WA; Fagbenro-Beyiku AF
    East Afr Med J; 1998 Apr; 75(4):237-42. PubMed ID: 9745842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Community-based treatment of onchocerciasis with ivermectin in southwest Nigeria: dermatological response to a singledose therapy.
    Osungbade KO; Asuzu MC; Kale OO
    Afr J Med Med Sci; 2001 Dec; 30(4):352-5. PubMed ID: 14510119
    [No Abstract]   [Full Text] [Related]  

  • 33. Adverse reactions to ivermectin treatment in Simulium neavei-transmitted onchocerciasis.
    Kipp W; Bamhuhiiga J; Rubaale T; Büttner DW
    Am J Trop Med Hyg; 2003 Dec; 69(6):621-3. PubMed ID: 14740878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Ivermectin with and without doxycycline on clinical symptoms of onchocerciasis.
    Masud H; Qureshi TQ; Dukley M
    J Coll Physicians Surg Pak; 2009 Jan; 19(1):34-8. PubMed ID: 19149978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. African Programme for Onchocerciasis Control (APOC): sociological study in three foci of central Africa before the implementation of treatments with ivermectin (Mectizan).
    Dimomfu BL; Lubeji DK; Noma M; Sékétéli A; Boussinesq M;
    Trans R Soc Trop Med Hyg; 2007 Jul; 101(7):674-9. PubMed ID: 17433391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Status of forest onchocerciasis in the Lower Cross River Basin, Nigeria: change in clinical and parasitological indices after 6 years of ivermectin intervention.
    Opara KN; Fagbemi BO; Atting IA; Oyene UE; Okenu DM
    Public Health; 2007 Mar; 121(3):202-7. PubMed ID: 17241647
    [No Abstract]   [Full Text] [Related]  

  • 37. A randomized, double-blind, controlled trial of the effects of ivermectin at normal and high doses, given annually or three-monthly, against Onchocerca volvulus: ophthalmological results.
    Fobi G; Gardon J; Kamgno J; Aimard-Favennec L; Lafleur C; Gardon-Wendel N; Duke BO; Boussinesq M
    Trans R Soc Trop Med Hyg; 2005 Apr; 99(4):279-89. PubMed ID: 15708387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemokines in onchocerciasis patients after a single dose of ivermectin.
    Fendt J; Hamm DM; Banla M; Schulz-Key H; Wolf H; Helling-Giese G; Heuschkel C; Soboslay PT
    Clin Exp Immunol; 2005 Nov; 142(2):318-26. PubMed ID: 16232219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of community prevalence of human onchocerciasis in the Amazonian onchocerciasis focus: Bayesian approach.
    Carabin H; Escalona M; Marshall C; Vivas-Martínez S; Botto C; Joseph L; Basáñez MG
    Bull World Health Organ; 2003; 81(7):482-90. PubMed ID: 12973640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact assessment study after 27 years of community-directed treatment with ivermectin in Galadimawa, Kaduna State, Nigeria.
    Babalola OE; Bassi A
    Niger Postgrad Med J; 2017; 24(1):14-19. PubMed ID: 28492204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.